Looks like a lot of gimme's in there. Advancement of corporate strategy? Completion of a study is a bonus? What does "advancing" Copaxone in the US mean when they filed in 2008? Why did they miss financial discipline? What exactly are they doing with Copaxone in the EU? I believe a clinical trial will be required.